Document is current
Any future updates will be listed below
-
Authors
Lavrova, Anna https://orcid.org/0009-0001-7521-7082
Pham, Nha Trang Thu
Vernon, Cynthia J.
Carlos, Arenn F.
Petersen, Ronald C.
Dickson, Dennis W.
Lowe, Val J.
Jack, Clifford R. Jr.
Whitwell, Jennifer L.
Josephs, Keith A.
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 AG37491-10)
Foundation for the National Institutes of Health (P50 AG16574)
Foundation for the National Institutes of Health (U01 AG006786)
- License Information
-
More Information
Article History
Received: 8 January 2024
Revised: 4 March 2024
Accepted: 6 March 2024
First Online: 5 April 2024
Declarations
:
: Anna Lavrova, Nha Trang Thu Pham and Cynthia J. Vernon reports no conflicts of interest. Dennis W. Dickson, Jennifer L. Whitwell, and Keith A. Josephs receive research support from the NIH/NIA/NINDS/NIDCD. Val J. Lowe consults for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). Ronald C. Petersen serves on data monitoring committees for Janssen Alzheimer Immunotherapy, and is a consultant for Biogen, Roche, Merck, and Genentech, Inc; receives publishing royalties from <i>Mild Cognitive Impairment</i> (Oxford University Press, 2003), and receives research support from the NIH/NIA. C.R. Jack, Jr. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
